Webbläsaren som du använder stöds inte av denna webbplats. Alla versioner av Internet Explorer stöds inte längre, av oss eller Microsoft (läs mer här: * https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Var god och använd en modern webbläsare för att ta del av denna webbplats, som t.ex. nyaste versioner av Edge, Chrome, Firefox eller Safari osv.

Default user image.

Katarina Sjögreen Gleisner

Professor

Default user image.

Variations in the practice of molecular radiotherapy and implementation of dosimetry : results from a European survey

Författare

  • Katarina Sjögreen Gleisner
  • Emiliano Spezi
  • Pavel Solny
  • Pablo Minguez Gabina
  • Francesco Cicone
  • Caroline Stokke
  • Carlo Chiesa
  • Maria Paphiti
  • Boudewijn Brans
  • Mattias Sandström
  • Jill Tipping
  • Mark Konijnenberg
  • Glenn Flux
Visa allt

Summary, in English

Background: Currently, the implementation of dosimetry in molecular radiotherapy (MRT) is not well investigated, and in view of the Council Directive (2013/59/Euratom), there is a need to understand the current availability of dosimetry-based MRT in clinical practice and research studies. The aim of this study was to assess the current practice of MRT and dosimetry across European countries. Methods: An electronic questionnaire was distributed to European countries. This addressed 18 explicitly considered therapies, and for each therapy, a similar set of questions were included. Questions covered the number of patients and treatments during 2015, involvement of medical specialties and medical physicists, implementation of absorbed dose planning, post-therapy imaging and dosimetry, and the basis of therapy prescription. Results: Responses were obtained from 26 countries and 208 hospitals, administering in total 42,853 treatments. The most common therapies were 131I-NaI for benign thyroid diseases and thyroid ablation of adults. The involvement of a medical physicist (mean over all 18 therapies) was reported to be either minority or never by 32% of the responders. The percentage of responders that reported that dosimetry was included on an always/majority basis differed between the therapies and showed a median value of 36%. The highest percentages were obtained for 177Lu-PSMA therapy (100%), 90Y microspheres of glass (84%) and resin (82%), 131I-mIBG for neuroblastoma (59%), and 131I-NaI for benign thyroid diseases (54%). The majority of therapies were prescribed based on fixed-activity protocols. The highest number of absorbed-dose based prescriptions were reported for 90Y microsphere treatments in the liver (64% and 96% of responses for resin and glass, respectively), 131I-NaI treatment of benign thyroid diseases (38% of responses), and for 131I-mIBG treatment of neuroblastoma (18% of responses). Conclusions: There is a wide variation in MRT practice across Europe and for different therapies, including the extent of medical-physicist involvement and the implementation of dosimetry-guided treatments.

Avdelning/ar

  • Nuclear Medicine Physics

Publiceringsår

2017-12-01

Språk

Engelska

Publikation/Tidskrift/Serie

EJNMMI Physics

Volym

4

Issue

1

Dokumenttyp

Artikel i tidskrift

Förlag

Springer

Ämne

  • Radiology, Nuclear Medicine and Medical Imaging
  • Other Physics Topics

Nyckelord

  • Dosimetry
  • European survey
  • Molecular radiotherapy
  • Radionuclide therapy
  • Radiopharmaceutical therapy

Aktiv

Published

Forskningsgrupp

  • Nuclear Medicine Physics

ISBN/ISSN/Övrigt

  • ISSN: 2197-7364